Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes - SCALE


The goal of the trial was to compare the safety and efficacy of liraglutide, a glucagon-like peptide 1 (GLP-1) analog, in affecting weight loss in patients with type 2 diabetes and obesity.

Contribution to the Literature: The SCALE trial showed that in obese patients with type 2 diabetes, liraglutide 3 mg and 1.8 mg daily both achieved greater weight loss and better glycemic control at 56 weeks, compared with placebo.